Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giorgio Cocconi

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Breast Cancer Research and Treatment|September 25, 2003
Adjuvant chemotherapy in early breast cancer: optimal and suboptimal anthracycline-containing regimensGiorgio Cocconi
Tumori|June 29, 2002
Independent clinical trials: a commentaryGiorgio Cocconi
Tumori|August 19, 2004
Design and development of new combinations of the CMF agents with taxanes (paclitaxel or docetaxel) in advanced breast cancer: a feasibility studyGiorgio Cocconi, Stefania Salvagni, Rodolfo Passalacqua, et al.
European Journal of Internal Medicine|December 28, 2005
Attitudes to, and practice of, unconventional medicine by physicians in ItalyGiorgio Cocconi, Caterina Caminiti, Sylvain Capriglia, et al.
Tumori|June 14, 2005
Hepatic artery administration of docetaxel in liver metastases from breast carcinoma: a feasibility studyGiorgio Cocconi, Alessandro Gamboni, Donatello Gasparro, et al.
Tumori|May 5, 2010
National survey of medical choices in caring for terminally ill patients in Italy, a cross-sectional studyGiorgio Cocconi, Caterina Caminiti, Giovanni Zaninetta, et al.
Cancer|April 2, 2005
Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphomaAntonino Musolino, Maria Antonietta Perrone, Maria Michiara, et al.
American Journal of Clinical Oncology|December 10, 2003
P-CHOP: cisplatin (P) added to the standard CHOP regimen as first-line treatment for aggressive non-Hodgkin lymphoma: a single-institution phase II studyGiorgio Cocconi, Vittorio Franciosi, Anna Dodero, et al.
Tumori|August 19, 2004
Early detection of recurrences in the follow-up of primary breast cancer in an asymptomatic or symptomatic phaseMaria Antonietta Perrone, Antonino Musolino, Maria Michiara, et al.
Acta Bio-Medica : Atenei Parmensis|March 12, 2008
Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus Interferon alpha-2a as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomised multicentre trialMatteo Dalla Chiesa, Rodolfo Passalacqua, Maria Michiara, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Breast Cancer Research and Treatment|September 25, 2003
Adjuvant chemotherapy in early breast cancer: optimal and suboptimal anthracycline-containing regimensGiorgio Cocconi
Tumori|June 29, 2002
Independent clinical trials: a commentaryGiorgio Cocconi
Tumori|August 19, 2004
Design and development of new combinations of the CMF agents with taxanes (paclitaxel or docetaxel) in advanced breast cancer: a feasibility studyGiorgio Cocconi, Stefania Salvagni, Rodolfo Passalacqua, et al.
European Journal of Internal Medicine|December 28, 2005
Attitudes to, and practice of, unconventional medicine by physicians in ItalyGiorgio Cocconi, Caterina Caminiti, Sylvain Capriglia, et al.
Tumori|June 14, 2005
Hepatic artery administration of docetaxel in liver metastases from breast carcinoma: a feasibility studyGiorgio Cocconi, Alessandro Gamboni, Donatello Gasparro, et al.
Tumori|May 5, 2010
National survey of medical choices in caring for terminally ill patients in Italy, a cross-sectional studyGiorgio Cocconi, Caterina Caminiti, Giovanni Zaninetta, et al.
Cancer|April 2, 2005
Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphomaAntonino Musolino, Maria Antonietta Perrone, Maria Michiara, et al.
American Journal of Clinical Oncology|December 10, 2003
P-CHOP: cisplatin (P) added to the standard CHOP regimen as first-line treatment for aggressive non-Hodgkin lymphoma: a single-institution phase II studyGiorgio Cocconi, Vittorio Franciosi, Anna Dodero, et al.
Tumori|August 19, 2004
Early detection of recurrences in the follow-up of primary breast cancer in an asymptomatic or symptomatic phaseMaria Antonietta Perrone, Antonino Musolino, Maria Michiara, et al.
Acta Bio-Medica : Atenei Parmensis|March 12, 2008
Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus Interferon alpha-2a as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomised multicentre trialMatteo Dalla Chiesa, Rodolfo Passalacqua, Maria Michiara, et al.
Pageof 2